Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study

PURPOSE: We examined the feasibility of using CYP2D6 genotyping to determine optimal tamoxifen dose and investigated whether the key active tamoxifen metabolite, endoxifen, could be increased by genotype-guided tamoxifen dosing in patients with intermediate CYP2D6 metabolism. PATIENTS AND METHODS: O...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Irvin, William J., Walko, Christine M., Weck, Karen E., Ibrahim, Joseph G., Chiu, Wing K., Dees, E. Claire, Moore, Susan G., Olajide, Oludamilola A., Graham, Mark L., Canale, Sean T., Raab, Rachel E., Corso, Steven W., Peppercorn, Jeffrey M., Anderson, Steven M., Friedman, Kenneth J., Ogburn, Evan T., Desta, Zeruesenay, Flockhart, David A., McLeod, Howard L., Evans, James P., Carey, Lisa A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2011
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3158597/
https://ncbi.nlm.nih.gov/pubmed/21768473
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.31.4427
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados